HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Call Could Be Regulators After hGH Direct Seller Ignores Industry Self-Regulation Process

Executive Summary

Direct seller New U Life may face regulatory scrutiny after two BBB National Programs, Inc. industry self-regulation programs reported it failed to stop using bogus health claims, including treating COVID-19.

You may also be interested in...



Risking FTC Scrutiny, Direct Seller Ignores Industry Self-Regulation Group On COVID-19 Claims

Direct seller Flavon USA is referred to FTC after it failed to respond to repeated outreach by Direct Selling Self-Regulatory Council over claims its supplements treat coronavirus. The watchdog asked for substantiation of claims suggesting products also could tumors and diabetes.

Federal Agencies Shut Down Church Group's Sales Of Bleach Mixture Promoted As COVID-19 Cure

The combination of Genesis II Church's rejection of FDA's warning, the potential for serious adverse events linked to its chlorine dioxide formulation and its claims the product treats COVID-19 led FDA to seek an injunction to stop sales of the product a week after it warned the group.

Somaderm 'FDA Registered' But Not 'Approved' – Similac-Enfamil Comparison Also Reviewed

Similac marketer Abbott Nutrition supports most but not all ad claims comparing its Human Milk Fortifier to Enfamil's; Council of Better Business Bureaus' investigative arms review claims comparing two baby probiotic drop brands and a protein digesting enzyme ad.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel